The prevalence of respiratory disorders is driving the growth of capnography equipment demand. In capnography, carbon dioxide (CO2) absorbs infrared radiation, and the procedure involves the passage of infrared radiation over a gas sample collected from exhalation. In many cases, oxygen levels in the blood can remain normal for several minutes after a patient stops breathing. The capnography detects the CO2 present in the body and the detection is more accurate. The equipment can read every phase of the respiratory cycle, thereby providing more in-depth readings. The ability of capnography machines to provide robust data sets makes it easier for healthcare providers to diagnose the root causes of respiratory problems. The capnograph wavelength displays the entire breathing cycle, making it easier to track exact symptoms. Capnography is used to understand how a patient is responding to treatment as they can display the ongoing data in real time. The continuous measurement of human respiratory CO2 by using a capnograph provides valuable information about cardiopulmonary resuscitation, endotracheal tube placement, pulmonary embolism, and procedural sedation. The equipment is also used to obtain information about the effect of air pollution on cardiopulmonary characteristics and the effectiveness of a treatment for a patient with respiratory distress. The changes in the shape of the capnogram are used to diagnose respiratory disease conditions, and changes in end-tidal CO2 (EtCO2)—i.e., the maximum CO2 concentration at the end of each tidal breath—can be used to assess disease severity and response to treatment.
Medtronic and Koninklijke Philips N.V. – Notable Market Players in Capnography Equipment Market
The capnography equipment market majorly consists of the players such as Medtronic, Koninklijke Philips N.V., General Electric Company, Dragerwerk AG & Co. KGaA, Nihon Kohden Corporation, Hill Rom Holding Inc. (Baxter), Masimo, SCHILLER Americas Inc., ICU MEDICAL Inc., BD. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized strategies such as product launches, expansions, and product upgradations for the growth of their organizations. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the capnography equipment market:
| Year | News |
| Jul-2020 | Welch Allyn (Hill Rom Holdings, Inc.) announced new product launch namely, “Connex® Vital Signs Monitor” that has intuitive touchscreen that is adaptable for most low-acuity healthcare environments and clinical workflows. The product can also track cardiac activity using 3-or-5 lead ECG monitoring, measure pulse oximeter, non-invasive blood pressure (NIBP), temperature, end-tidal CO2 (EtCO2), respiration, and many more. |
| Jun-2022 | GE Healthcare announced clearance and CE mark for the integration of advanced INVOS regional oximetry and Microstream capnography technologies on the CARESCAPE precision monitoring platform. The partnership aims for longstanding collaboration with Medtronic allows GE Healthcare to integrate clinically advanced parameters to enable clinicians with precision monitoring for individualized care. |
| Dec-2019 | Masimo announced partnership with Drager where Drager will integrate additional Masimo measurement technologies into Drager’s family of multi-parameter patient monitors, for assisting clinicians assess brain function, oxygenation, and ventilation status |
| Jan-2022 | ICU Medical, Inc. announced acquisition with Smiths Medical. The acquisition aims to combine companies creating a leading infusion therapy company with estimated pro forma accounting considerable revenue of approximately US$2.5 billion |
| May-2020 | Masimo and Royal Philips announced partnership for integrating Masimo measurement technologies into select IntelliVue® MX-series multi-parameter monitors, to help clinicians assess cerebral oximetry and ventilation status.In 2016, Masimo and Philips entered into a multi-year business partnership involving both companies’ innovations in patient monitoring and therapy solutions. Now, in 2020, Philips becomes one of Masimo’s first industry partners to launch additional advanced Masimo measurements, NomoLine and O3, in their own patient monitors, sharing Masimo’s expertise in capnography and regional cerebral oximetry with caregivers and patients around the world |
| Jul-2021 | Spacelabs Healthcare, a division of OSI Systems Inc. announced partnership with Masimo for integrating SET Pulse Oximetery, NomoLine capnography, rainbow SET Pulse CO-Oximetry, SedLine brain function monitoring, and O3 regional oximetry into select Spacelabs multi-parameter monitors |
